TWI652260B - 用以合成甲狀腺激素類似物及其多形體之方法 - Google Patents

用以合成甲狀腺激素類似物及其多形體之方法 Download PDF

Info

Publication number
TWI652260B
TWI652260B TW102133687A TW102133687A TWI652260B TW I652260 B TWI652260 B TW I652260B TW 102133687 A TW102133687 A TW 102133687A TW 102133687 A TW102133687 A TW 102133687A TW I652260 B TWI652260 B TW I652260B
Authority
TW
Taiwan
Prior art keywords
compound
formula
acid
item
batch
Prior art date
Application number
TW102133687A
Other languages
English (en)
Chinese (zh)
Other versions
TW201425300A (zh
Inventor
迪 海斯特二世
Ii D. Keith Hester
羅伯特 杜蓋德
Robert J. Duguid
瑪沙 凱利
Martha J. Kelly
安娜 加斯諾夫
Anna CHASNOFF
董剛
Gang Dong
愛德恩 克羅
Edwin L. Crow
雷貝卡 塔伯
Rebecca Taub
查理斯 雷諾
Charles H. Reynolds
崔德舜
Duk Soon Choi
聯合 舒
Lianhe Shu
王平
Ping Wang
Original Assignee
美商瑪德瑞高製藥公司
Madrigal Pharmaceuticals, Inc.
瑞士商赫夫曼羅氏股份有限公司
F. Hoffmann-La Roche Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商瑪德瑞高製藥公司, Madrigal Pharmaceuticals, Inc., 瑞士商赫夫曼羅氏股份有限公司, F. Hoffmann-La Roche Ltd filed Critical 美商瑪德瑞高製藥公司
Publication of TW201425300A publication Critical patent/TW201425300A/zh
Application granted granted Critical
Publication of TWI652260B publication Critical patent/TWI652260B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
TW102133687A 2012-09-17 2013-09-17 用以合成甲狀腺激素類似物及其多形體之方法 TWI652260B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261702137P 2012-09-17 2012-09-17
US61/702,137 2012-09-17
US201361790432P 2013-03-15 2013-03-15
US61/790,432 2013-03-15

Publications (2)

Publication Number Publication Date
TW201425300A TW201425300A (zh) 2014-07-01
TWI652260B true TWI652260B (zh) 2019-03-01

Family

ID=50278769

Family Applications (4)

Application Number Title Priority Date Filing Date
TW107137798A TWI681957B (zh) 2012-09-17 2013-09-17 用以合成甲狀腺激素類似物及其多形體之方法
TW110117935A TWI804870B (zh) 2012-09-17 2013-09-17 用以合成甲狀腺激素類似物及其多形體之方法
TW102133687A TWI652260B (zh) 2012-09-17 2013-09-17 用以合成甲狀腺激素類似物及其多形體之方法
TW108132827A TWI755628B (zh) 2012-09-17 2013-09-17 用以合成甲狀腺激素類似物及其多形體之方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TW107137798A TWI681957B (zh) 2012-09-17 2013-09-17 用以合成甲狀腺激素類似物及其多形體之方法
TW110117935A TWI804870B (zh) 2012-09-17 2013-09-17 用以合成甲狀腺激素類似物及其多形體之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW108132827A TWI755628B (zh) 2012-09-17 2013-09-17 用以合成甲狀腺激素類似物及其多形體之方法

Country Status (23)

Country Link
US (8) US9266861B2 (enExample)
EP (4) EP2895466B1 (enExample)
JP (8) JP6616688B2 (enExample)
KR (4) KR102363776B1 (enExample)
CN (2) CN108101851A (enExample)
AR (1) AR092872A1 (enExample)
AU (1) AU2013315017C1 (enExample)
BR (2) BR112015005891A2 (enExample)
CA (3) CA2884481C (enExample)
DK (3) DK4406594T3 (enExample)
ES (2) ES2795450T3 (enExample)
FI (1) FI4406594T3 (enExample)
IL (7) IL314360B2 (enExample)
IN (1) IN2015DN03133A (enExample)
MX (2) MX364661B (enExample)
MY (1) MY170520A (enExample)
NZ (2) NZ739645A (enExample)
PT (1) PT4406594T (enExample)
RU (2) RU2668960C2 (enExample)
SG (3) SG10201705984XA (enExample)
TW (4) TWI681957B (enExample)
WO (1) WO2014043706A1 (enExample)
ZA (1) ZA201501795B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
CN110167557A (zh) * 2016-10-18 2019-08-23 马德里加尔制药公司 用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法
EP3725779A4 (en) * 2018-01-23 2021-02-24 Shenzhen TargetRx, Inc. SUBSTITUTED PYRIDAZINONE COMPOUND
EP3807267B1 (en) 2018-06-12 2025-03-19 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
US20210292304A1 (en) * 2018-06-22 2021-09-23 Hinova Pharmaceuticals Inc. Deuterated mgl-3196 compound and use thereof
TW202019914A (zh) 2018-07-02 2020-06-01 美商瑪德瑞高製藥公司 ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式
EP3864013A4 (en) * 2018-10-12 2022-09-28 InventisBio Co., Ltd. Thyroid hormone receptor agonists
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
US12338206B2 (en) 2019-02-21 2025-06-24 Nanjing Ruijie Pharma Co., Ltd. Compounds and their uses as thyroid hormone receptor agonists
SI3965884T1 (sl) * 2019-05-08 2025-05-30 Aligos Therapeutics, Inc. Modulatorji thr-beta z glavno skupino dioxo-1,2,4-triazil
CN111909137B (zh) * 2019-05-10 2023-05-30 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
CN114174282A (zh) * 2019-05-29 2022-03-11 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
WO2021043185A1 (en) * 2019-09-04 2021-03-11 Sunshine Lake Pharma Co., Ltd. A compound as a thyroid hormone beta receptor agonist and use thereof
EP4028008A4 (en) 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN112707892A (zh) * 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
TWI763147B (zh) * 2019-11-26 2022-05-01 大陸商昆藥集團股份有限公司 1，2，4-三嗪-3，5-二酮類化合物及其製備方法和應用
WO2021121210A1 (zh) * 2019-12-16 2021-06-24 江苏恒瑞医药股份有限公司 并环类衍生物、其制备方法及其在医药上的应用
CN114787153A (zh) 2019-12-26 2022-07-22 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
WO2022041026A1 (en) * 2020-08-27 2022-03-03 InventisBio Co., Ltd. Pyridazinone compounds
CA3192243A1 (en) * 2020-09-10 2022-03-17 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of resmetirom, preparation method therefor, and use thereof
US20230364099A1 (en) 2020-10-19 2023-11-16 Teva Pharmaceuticals International Gmbh Solid state forms of resmetirom
CN114437042A (zh) * 2020-11-03 2022-05-06 深圳微芯生物科技股份有限公司 酞嗪类化合物的晶型及其制备方法
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
JP2024506848A (ja) * 2021-02-01 2024-02-15 マドリガル ファーマシューティカルズ インコーポレイテッド 肝障害又は脂質障害の治療のためのロスバスタチンとレスメチロムの治療的組み合わせ
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
WO2023049491A1 (en) 2021-09-27 2023-03-30 Madrigal Pharmaceuticals, Inc. Resmetirom for reducing liver volume
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
KR20250166323A (ko) 2023-04-07 2025-11-27 테른스 파마슈티칼스, 인크. 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합
CN116768802B (zh) * 2023-05-25 2025-11-21 杭州科巢生物科技有限公司 一种瑞司美替罗的合成方法
US20240423992A1 (en) 2023-06-22 2024-12-26 Madrigal Pharmaceuticals, Inc. Biomarkers for treating liver disorders with thr-b agonists and related uses
CN119613386A (zh) * 2023-09-14 2025-03-14 杭州科巢生物科技有限公司 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法
CN117263870A (zh) * 2023-09-21 2023-12-22 江西同和药业股份有限公司 一种Resmetirom关键中间体III的制备方法
WO2025083699A2 (en) 2023-10-16 2025-04-24 Cipla Limited Resmetirom polymorphs and process thereof
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025164161A1 (ja) * 2024-01-29 2025-08-07 シオノギファーマ株式会社 カンナビジオールの溶媒和物及びカンナビジオールの精製方法
WO2025171032A1 (en) 2024-02-06 2025-08-14 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025191457A1 (en) * 2024-03-13 2025-09-18 Morepen Laboratories Limited Process for the preparation of pyridazinone derivative
CN119306670A (zh) * 2024-10-12 2025-01-14 北京海美桐医药科技有限公司 瑞司美替罗中间体、其合成方法和瑞司美替罗的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228135A (zh) 2005-07-21 2008-07-23 霍夫曼-拉罗奇有限公司 作为甲状腺激素受体激动剂的哒嗪酮衍生物
CN101801960A (zh) 2007-09-20 2010-08-11 霍夫曼-拉罗奇有限公司 甲状腺激素类似物的前药

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5615272A (en) * 1979-07-17 1981-02-14 Ishihara Sangyo Kaisha Ltd N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
KR100856819B1 (ko) * 2003-01-28 2008-09-05 아카데미슈 지켄후이스 라이덴 Ｌｌ―37 유래의 펩티드성 독소 억제제
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
US7807647B2 (en) * 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
US20080152700A1 (en) 2004-06-01 2008-06-26 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
EP2592075B1 (en) 2004-11-02 2015-04-29 Northwestern University Pyridazine compounds for the treatment of inflammatory diseases
HRP20100611T1 (hr) * 2007-06-06 2010-12-31 Torrent Pharmaceuticals Ltd Novi spojevi
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
US8858502B2 (en) 2012-10-10 2014-10-14 Alcon Research, Ltd. Systems and methods for external pressure sensing
CN106132969A (zh) 2014-02-14 2016-11-16 森普拉制药公司 用于治疗糖尿病和肝病的组合物和方法
CN110167557A (zh) 2016-10-18 2019-08-23 马德里加尔制药公司 用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法
EP3807267B1 (en) 2018-06-12 2025-03-19 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
TW202019914A (zh) 2018-07-02 2020-06-01 美商瑪德瑞高製藥公司 ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式
EP3864013A4 (en) 2018-10-12 2022-09-28 InventisBio Co., Ltd. Thyroid hormone receptor agonists
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228135A (zh) 2005-07-21 2008-07-23 霍夫曼-拉罗奇有限公司 作为甲状腺激素受体激动剂的哒嗪酮衍生物
CN101801960A (zh) 2007-09-20 2010-08-11 霍夫曼-拉罗奇有限公司 甲状腺激素类似物的前药

Also Published As

Publication number Publication date
AU2013315017B2 (en) 2017-07-27
IL288133A (en) 2022-01-01
KR20200023528A (ko) 2020-03-04
TW201425300A (zh) 2014-07-01
JP2020109090A (ja) 2020-07-16
RU2015114327A (ru) 2016-11-10
FI4406594T3 (fi) 2025-11-26
JP2025179154A (ja) 2025-12-09
JP2024056793A (ja) 2024-04-23
EP2895466A4 (en) 2016-08-10
US9968612B2 (en) 2018-05-15
CN105008335A (zh) 2015-10-28
US20210161904A1 (en) 2021-06-03
US20150203473A1 (en) 2015-07-23
TW201906835A (zh) 2019-02-16
JP7038745B2 (ja) 2022-03-18
EP4406594A2 (en) 2024-07-31
IL275393B (en) 2022-01-01
IL259610B (en) 2020-06-30
US20240122936A1 (en) 2024-04-18
US10894050B2 (en) 2021-01-19
US20190381053A1 (en) 2019-12-19
RU2668960C2 (ru) 2018-10-05
IN2015DN03133A (enExample) 2015-10-02
JP2022078218A (ja) 2022-05-24
IL314360B1 (en) 2025-05-01
TWI804870B (zh) 2023-06-11
IL288133B1 (en) 2024-08-01
EP4023641B1 (en) 2024-05-01
CA3111317A1 (en) 2014-03-20
US20180228807A1 (en) 2018-08-16
IL288133B2 (en) 2024-12-01
NZ705827A (en) 2018-07-27
EP2895466A1 (en) 2015-07-22
SG11201501907YA (en) 2015-04-29
CA3111317C (en) 2023-08-29
JP7436542B2 (ja) 2024-02-21
IL314360A (en) 2024-09-01
EP4406594B1 (en) 2025-09-10
EP4023641A3 (en) 2022-09-14
JP6616688B2 (ja) 2019-12-04
JP2018080188A (ja) 2018-05-24
CN105008335B (zh) 2018-12-21
JP2015535817A (ja) 2015-12-17
NZ739645A (en) 2019-11-29
KR102138750B1 (ko) 2020-07-29
EP4023641A2 (en) 2022-07-06
US11986481B2 (en) 2024-05-21
MY170520A (en) 2019-08-08
KR20180131647A (ko) 2018-12-10
TW201946917A (zh) 2019-12-16
IL320269A (en) 2025-06-01
AU2013315017A1 (en) 2015-04-02
IL265030B (en) 2020-07-30
SG10201705984XA (en) 2017-08-30
IL237628A0 (en) 2015-04-30
IL275393A (en) 2020-07-30
BR112015005891A2 (pt) 2017-08-08
US11564926B2 (en) 2023-01-31
KR102363776B1 (ko) 2022-02-15
WO2014043706A8 (en) 2017-10-19
DK3689853T3 (da) 2022-03-07
US20230210856A1 (en) 2023-07-06
PT4406594T (pt) 2025-11-28
DK4406594T3 (da) 2025-11-03
BR122021024202B1 (pt) 2022-05-17
JP2020015739A (ja) 2020-01-30
CN108101851A (zh) 2018-06-01
MX2018014924A (es) 2020-09-02
CA3090070A1 (en) 2014-03-20
US9266861B2 (en) 2016-02-23
EP3689853B1 (en) 2021-11-24
JP2019048856A (ja) 2019-03-28
SG10202006058QA (en) 2020-08-28
CA2884481C (en) 2021-04-27
KR20210083381A (ko) 2021-07-06
ES2795450T3 (es) 2020-11-23
MX2015003418A (es) 2016-04-04
HK1212682A1 (en) 2016-06-17
IL237628B (en) 2019-07-31
CA3090070C (en) 2023-01-24
EP4406594A3 (en) 2024-11-06
DK2895466T3 (da) 2020-06-08
ES2907926T3 (es) 2022-04-27
JP6765408B2 (ja) 2020-10-07
MX364661B (es) 2019-05-03
KR20150056630A (ko) 2015-05-26
KR101966490B1 (ko) 2019-08-14
IL314360B2 (en) 2025-09-01
TW202134217A (zh) 2021-09-16
TWI681957B (zh) 2020-01-11
AU2013315017C1 (en) 2017-11-23
EP3689853A1 (en) 2020-08-05
CA2884481A1 (en) 2014-03-20
TWI755628B (zh) 2022-02-21
US20160243126A1 (en) 2016-08-25
MX395148B (es) 2025-03-24
AR092872A1 (es) 2015-05-06
EP2895466B1 (en) 2020-03-25
US10376517B2 (en) 2019-08-13
WO2014043706A1 (en) 2014-03-20
RU2018128393A (ru) 2019-03-14
JP6532931B2 (ja) 2019-06-19
JP6899413B2 (ja) 2021-07-07
US20240148742A1 (en) 2024-05-09
ZA201501795B (en) 2021-10-27
RU2018128393A3 (enExample) 2019-04-16
IL259610A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
TWI652260B (zh) 用以合成甲狀腺激素類似物及其多形體之方法
HK40113302B (en) Thyroid hormone analogs
HK40113302A (en) Thyroid hormone analogs
HK40077432B (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
HK40077432A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
HK40033715B (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
HK40033715A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
HK1212682B (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof